Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

BI exercises option to acquire Austrian oncolytic virus company ViraTherapeutics

Executive Summary

Stemming from an ongoing two year collaboration between Boehringer Ingelheim GMBH and ViraTherapuetics GMBH, the former has chosen to exercise its option to acquire the latter for €210mm ($245mm).
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Cash
    • Full Acquisition
    • Acquisition of Private Biotech

Related Companies

Advertisement
UsernamePublicRestriction

Register